You just read:

Dompé receives FDA approval of Oxervate™ eye drops (cenegermin-bkbj ophthalmic solution), first-in-class recombinant human nerve growth factor with potential to completely heal rare neurotrophic keratitis

News provided by

Dompé U.S., Inc.

Aug 22, 2018, 22:35 ET